Ambrilia Validates its Targeted Delivery Technology for Cancer in Vivo

MONTREAL, QUEBEC--(Marketwire - June 19, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) today reported that it demonstrated and validated the in vivo proof-of-concept with its NGR-delivery technology applied to a carrier containing a siRNA (small interfering RNA). Data in animal tumor models showed efficient siRNA delivery to the tumor tissue, internalization and suppression of a cancer-promoting gene (oncogene). Such genes are essential to the growth of a number of tumors. In the past years, a number of oncogenes have been suppressed with RNA interference (RNAi), which can be achieved by siRNAs, showing the potential for therapeutic applications in humans.

"This validation represents another significant step forward in our strategy execution for our NGR-directed delivery technology. This latest in vivo proof-of-concept completes our investigation process ahead of schedule. It demonstrates the validation of our targeting peptide for selective and efficient delivery of siRNA, or other anti-cancer agents, thus giving us the green light to intensify our divestment efforts for this asset," said Dr. Philippe Calais, President and CEO. "As delivery remains a major hurdle in siRNA therapeutic developments, this versatile technology has significant potential for any Company active in this field, and now positions Ambrilia well for divestment".

About the NGR-Delivery Technology

Ambrilia's targeted delivery technology uses a proprietary NGR-containing peptide coupled with a drug loaded carrier such as a liposome, a nanoparticle, or other. When the NGR-containing peptide is coated onto a carrier, it results in a selective delivery and internalization of that carrier, and release of the therapeutic load (siRNA or other therapeutics in cancer treatment) in the targeted cells. Ambrilia's NGR-containing peptide has shown specific interactions with a receptor (APN/CD13) which is expressed in many types of cancer cells (melanoma, renal, pancreas, colon, prostate, gastric and thyroid). Furthermore, the carrier, coated with the NGR-containing targeting peptide, enhances the stability of siRNA in vivo, which could lead to improved therapeutic activity.

The Company had previously established a proof-of-concept with doxorubicin, a cytotoxic drug used in cancer treatment, and shown its efficient delivery in animal solid tumor models. Ambrilia aims to divest its NGR-delivery technology by the end of 2008.

Ambrilia's strategy is to capitalize on its broad product portfolio and original expertise in virology. During the course of 2008, execution of the strategy aims to monetize the non-virology assets through third parties agreements, in turn strengthening the Company's financial position to continue building its novel pipeline of antivirals.

AMBRILIA'S FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. There is a risk that expectations and forward looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on these forward-looking statements as they involve risks and uncertainties, which could make actual results differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's annual information form which contains a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, a HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, HCV entry and polymerase inhibitors and Anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.